Add nostrils and vaginas to the readily expanding list of human tissues doctors can now grow in laboratories and successfully implant in patients.
Two long-term studies just published in the influential medical journal The Lancet outline the success doctors have achieved in transplanting both body parts. In the first study, doctors at Wake Forest University harvested cells from the genitals of four teenage girls born with a syndrome that results in underdeveloped sexual organs, coaxed those cells into a regenerative state, grew them on a scaffold, and then transplanted the resulting tissue.
After eight years of follow up, “the organs continue to function as if they were native tissue and all recipients are sexually active, report no pain, and are satisfied with their desire/arousal, lubrication, and orgasm.”
In the second study, five people had their nostrils reconstructed with their own cartilage. That tissue was harvested from their own noses, and coaxed into expanding in volume by a factor of 40. It was then implanted. The research concludes that “the clinical reconstruction of the nasal [lobe] after resection of a non-melanoma skin cancer is safe and feasible.”
While these findings are certainly eyebrow-raising — and lend hope to those suffering with disfiguration — the more important aspect of their publication can be found in an op-ed published alongside the research.
Drs. Martin A. Birchall, and Alexander M. Seifalian write that these findings can be just as frustrating as they are promising. This research is considered disruptive medicine, and disruptions can take a very, very long time to make their way into mainstream medicine. And the high cost of developing such technology often poses roadblocks. Birchall and Seifalian write:
MRI scanners continue to improve generationally. These changes, which improve the patient’s experience and accuracy of diagnosis, are sustaining innovations: they improve an existing system that is understood by patients and that supports specialised industry, doctors, and health-care systems. By contrast, tissue engineering, and the various shades of regenerative and cellular therapies it partners, is a disruptive technology. …
Early automobile technology, although highly innovative, was the preserve of those who could afford it for many years. It was only when Henry Ford’s mass production brought automobiles to everyone’s street, in numbers yet at affordable cost, that the industry of the horse-drawn carriage passed away. These two Lancet studies show that those who practise conventional tissue reconstruction and organ transplantation, and the health-care and commercial industries which support them, should finally be taking the quirky minnows of tissue engineering quite seriously. Disruptive innovation might be nigh.
As I wrote in November, it will be some time before lab-grown organs are commonly available. Clinical trials for new procedures take decades. And “private industry is going to have to raise millions and millions of dollars not around the science, but around the practicality,” William Wagner, director of regenerative medicine at the University of Pittsburgh, told me then.
Roadblocks involving time and money are not exclusive to regenerative medicine. Take antibiotic research. Approvals of new antibiotics are currently at their lowest rate, at a time when threat of drug-resistant strains haven’t been higher. Or even sunscreen. Ingredients that European companies have been using for years, which work better than the ones currently available in the United States, are stuck in regulatory limbo.
That’s why Birchall and Seifalian provide a good reminder: Let’s turn some of these gee-whiz studies into reality.
What We're Following See More »
The House voted down the otherwise uncontroversial Energy and Water appropriations bill Thursday after Democrats succeeded in attaching an amendment affirming LGBT job discrimination protections for military contractors. More than 40 Republicans supported the amendment, but when it came to vote on the bill, 130 Republicans joined all but six Democrats to sink the bill. Speaker Paul Ryan said Democrats voting against the bill after securing the amendment shows their intention was to scuttle the process. Democrats, however, blamed other so-called poison-pill amendments for their votes against the bill. Nonetheless, Ryan said he intends to continue the appropriations process.
"It's about time for unity," said UAW President Dennis Williams. "We're endorsing Hillary Clinton. She's gotten 3 million more votes than Bernie, a million more votes than Donald Trump. She's our nominee." He called Sanders "a great friend of the UAW" while saying Trump "does not support the economic security of UAW families." Some 28 percent of UAW members indicated their support for Trump in an internal survey.
"Airport screening delays have caused more than 70,000 American Airlines customers and 40,000 checked bags to miss their flights this year, an executive for the airline told a U.S. congressional subcommittee on Thursday. A shortage of staff and a surge in air travelers have created a nightmare scenario for the U.S. Transportation Security Administration (TSA), with airport wait times in places like Chicago stretching beyond two hours."
"Donald Trump on Thursday reached the number of delegates needed to clinch the Republican nomination for president, completing an unlikely rise that has upended the political landscape and sets the stage for a bitter fall campaign. Trump was put over the top in the Associated Press delegate count by a small number of the party's unbound delegates who told the AP they would support him at the convention."
That the minority leader curses the Senate with his "cancerous leadership." After Reid tried to halt a defense bill, Cotton took to the floor and blasted Reid, adding, "As a junior senator, I preside over the Senate. I usually do in the morning, which means I'm forced to listen to the bitter, vulgar, incoherent ramblings of the Minority Leader. Normally, like other Americans, I ignore them."